Thursday, December 29, 2022
Selective Thyroid Hormone Receptor-Beta Agonists, Processes for Manufacturing or Relating to Same, and Products Containing Same
Kecia J. Reynolds
Paul Hastings LLP
Viking Therapeutics, Inc.
Letter to Katherine M. Hiner, Acting Secretary, USITC; requesting that the Commission conduct an investigation under section 337 of the Tariff Act of 1930, as amended, regarding certain selective thyroid hormone receptor-beta agonists, processes for manufacturing or relating to same, and products containing same. The proposed respondents are Ascletis Pharma Inc., China; Ascletis Pharmaceuticals Co. Ltd., China; Ascletis Bioscience Co., Ltd., China; Gannex Pharma Co., Ltd., China; and Jinzi Jason Wu, Seattle, WA.